Three months of octreotide treatment decreases gastric acid secretion and argyrophil cell density in patients with Zollinger‐Ellison syndrome and antral G‐cell hyperfunction

Alimentary Pharmacology & Therapeutics

Volumn 8, Issue 1, 1994, Pages 95-104

  ANNIBALE, B ^a   FAVE, G DELLE ^a   AZZONI, C ^b   CORLETO, V ^a   CAMBONI, G ^a   D'AMBRA, G ^b   PILATO, F P ^c   BORDI, C ^c  

^a Cattedra di Gastroenterologia I ^*

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c UNIVERSITY OF PARMA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GASTRIN; OCTREOTIDE;

ADULT; ARTICLE; CLINICAL ARTICLE; FEMALE; GASTRIN CELL; HUMAN; MALE; STOMACH ACID SECRETION; SUBCUTANEOUS DRUG ADMINISTRATION; ZOLLINGER ELLISON SYNDROME;

ADMINISTRATION, ORAL; ADULT; CELL COUNT; ENTEROCHROMAFFIN CELLS; FEMALE; GASTRIC ACID; GASTRINS; HUMAN; MALE; MIDDLE AGE; OCTREOTIDE; PYLORIC ANTRUM; SOMATOSTATIN; SUPPORT, NON-U.S. GOV'T; ZOLLINGER-ELLISON SYNDROME;

EID: 0028289507     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.1994.tb00165.x     Document Type: Article

References (40)

1. Regulation of gastrointestinal growth
2. Parietal and chief cell populations in four cases of the Zollinger‐Ellison syndrome
3. Zollinger‐Ellison Syndrome
4. Medical treatment of Antral gastrin cell hyperfunction: role of nonantisecretory therapy
5. Gastric endocrine cells proliferation: association with Zollinger‐Ellison syndrome
6. Gastric endocrine cell behavior in Zollinger‐Ellison patients upon long‐term potent antisecretory treatment
7. Carcinoid (ECL cell) tumor of the oxyntic mucosa of the stomach: a hormone‐dependent neoplasm
8. Gastric argyrophil carcinoidosis in patients with Zollinger‐Ellison syndrome due to type I multiple endocrine neoplasia
9. Relation between circulating gastrin and endocrine cell proliferation in the atrophic gastric fundic mucosa
10. ECL proliferation and gastric levels
11. Circulating gastrin, endocrine cells, histamine content, and histidine decarboxylase activity in atrophic gastritis
12. The effect of Zollinger‐Ellison Syndrome and omeprazole therapy on gastric oxyntic endocrine cells
13. Do histamine‐storing cells in the gastric mucosa mediate the acid‐stimulating action of gastrin
14. Activation and proliferation of gastric endocrine cells
15. Paracrine regulation of gastric acid secretion by fundic somatostatin
16. Effect of somatostatin on normal and gastrin‐stimulated cell proliferation in the gastric and intestinal mucosae of the rat
17. Long‐term effect of somatostin 14 on mouse stomach, antrum, intestine and exocrine pancreas
18. Diminishing efficacy of octreotide (SMS 201–995) on gastric functions of healthy subjects during one‐week administration
19. Observations on the effect of somatostatin analog in the Zollinger‐Ellison syndrome: implications for the treatment of apudomas
20. Sandostatin and gastroenteropancreatic endocrine tumors–therapeutic characteristics
21. Long‐acting somatostatin (SMS 201–995) in the management of Zollinger‐Ellison Syndrome: evidence for sustained efficacy
22. Morphometry of gastric endocrine cells in hypergastrinemic patients treated with the somatostatin analogue octreotide
23. Secretin injection test in the diagnosis of gastrinoma
24. Effect of bombesin on gastrin and gastric acid secretion in patients with duodenal ulcer
25. Pharmacokinetics of SMS 201–995 in healthy subjects
26. Quantitative ultra‐structure of endocrine cells of oxyntic mucosa in Zollinger‐Ellison syndrome
27. Ultrastructural morphometry of gastric endocrine cells before and after omeprazole
28. A silver nitrate stain for alpha‐2 cells in human pancreatic islets
29. Use of abitin‐biotin‐peroxidase complex (ABC) in immunoperoxidase technique
30. Quantitative electron microscopy of endocrine cells in oxyntic mucosa of normal human stomach
31. Reversible sustained increase of gastrin and gastric acid secretion in a subgroup of duodenal ulcer patients on long‐term treatment with H2 antagonists
32. Escape of the response to a long‐acting somatostatin analogue (SMS 210–995) in patients with Vipoma
33. Action of somatostatin analogue (SMS 201–995) on the growth‐promoting effect resulting from sustained achlorhydria in rat gastric mucosa, with special reference to endocrine cell behaviour
34. Gastrin‐dependent inhibitory effects of octreotide on the genesis of gastric ECLomas
35. Zollinger‐EIIison Syndrome
36. 2‐receptor antagonists: a prospective study
37. Mechanism for direct inhibition of canine gastric parietal cells by somatostatin